OncoSec Appoints Industry Leading Electroporation Device Expert, Jeffrey Silverman, as Vice President of Product Engineering prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Police activity reported April 22-May 4:
May 4, 9:21 a.m. A truck was speeding recklessly through the lawn at 19 Massachusettes Ave. and an altercation between two men, who both left the scene, was reported.
May 2, 7:59 a.m. Police responded to a call about a suspicious man drinking alcohol in Poland Woods near the bridge.
April 29, 11 p.m. Joshua D. Stephens, 27, 2146 East Park Drive, Uniontown, was cited for excessive speed (74 mph in a 25 mph zone), peeling tires and reckless operation following a traffic stop on U.S. 224.
5:50 p.m. A vehicle window was broken at Martial Arts Training Center, 15 W. McKinley Way. The owners were told that if anything was found missing, to report it.
Sirtex Medical announces collaboration update with OncoSec Medical
News provided by
Share this article
TAVO™ for the treatment of advanced melanoma
WOBURN, Mass., Jan. 19, 2021 /PRNewswire/
Sirtex Medical US Holdings, Inc. ( Sirtex ), a leading manufacturer of targeted cancer therapies, announced an advancement in its strategic collaboration with OncoSec Medical, Inc. (NASDAQ: ONCS) relating to OncoSec s lead product candidate TAVO™ (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system.
The collaboration update provides Sirtex with the option to acquire the right to co-promote TAVO™ and its related EP gene delivery system in the United States in the lead target indication of treating anti-PD-1 refractory locally advanced or metastatic melanoma. Sirtex has the right to exercise the option until 90 days following the filing of a Biologics License Application (BLA) by OncoSec.